CAR-T Referral Process: Insights from Emory

home / around-the-practice / car-t-referral-process-insights-from-emory

Panelists discuss how the CAR-T referral process for relapsed/refractory multiple myeloma involves careful patient selection, bridging therapy, and coordination between community and academic centers to optimize treatment outcomes.

$Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma$

EP. 1: Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, FACP;Ajay K. Nooka, MD;Nisha Joseph, MD;Jonathan Kaufman, MD

December 20th 2024

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.

EP. 2: Patient Selection and Referral Eligibility for CAR-T Therapy

Sagar Lonial, MD, FACP;Ajay K. Nooka, MD;Nisha Joseph, MD;Jonathan Kaufman, MD

January 3rd 2025

Panelists discuss the key factors that influence their institution's decision to utilize CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma and explain the next steps they would take if choosing CAR-T, including the rationale behind their decisions.